2-(2,5-二甲基苯并咪唑-1-基)乙醇 | 835627-61-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-(2,5-二甲基苯并咪唑-1-基)乙醇
• 英文名称: 1-(2-hydroxyethyl)-2,3-dimethylbenzimidazole
• 英文别名: 2-(2,5-Dimethyl-1H-benzimidazol-1-yl)ethan-1-ol；2-(2,5-dimethylbenzimidazol-1-yl)ethanol
• CAS: 835627-61-7
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: PWOGCSFPPMWBRL-UHFFFAOYSA-N

物化性质

• 熔点：
  131-133 °C
• 沸点：
  388.3±25.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2,5-二甲基苯并咪唑-1-基)乙醇 在 硝酸 作用下， 20.0 ℃ 、344.74 kPa 条件下， 反应 4.5h， 生成 6-乙酰氨基-1-(2-乙酰氧基乙基)-2,3-二甲基-7-硝基苯并咪唑
  参考文献：
  名称：

  Synthesis of imidazo[1,5,4-de]quinoxalin-9-ones, benzimidazole analogues of pyrroloiminoquinone marine natural products

  摘要：

  The imidazoquinoxalinones 1 and 2 are benzimidazole analogues of indole-based marine natural products called makaluvamins. The stabilized cation 1 and the zwitterion 2 were prepared in similar to9 steps from readily available starting materials. Compound 1 is more cytostatic and cytotoxic than 2 and also shows activity in the hollow fiber assay. Unlike the indole-based natural products, 1 and 2 are not potent topoisomerase II inhibitors. Their pattern of cytotoxic and cyostatic activity could be related to inhibition of protein tyrosine kinases. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.10.016
• 作为产物：
  描述：

  4-溴-3-硝基甲苯 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 反应 9.0h， 生成 2-(2,5-二甲基苯并咪唑-1-基)乙醇
  参考文献：
  名称：

  Synthesis of imidazo[1,5,4-de]quinoxalin-9-ones, benzimidazole analogues of pyrroloiminoquinone marine natural products

  摘要：

  The imidazoquinoxalinones 1 and 2 are benzimidazole analogues of indole-based marine natural products called makaluvamins. The stabilized cation 1 and the zwitterion 2 were prepared in similar to9 steps from readily available starting materials. Compound 1 is more cytostatic and cytotoxic than 2 and also shows activity in the hollow fiber assay. Unlike the indole-based natural products, 1 and 2 are not potent topoisomerase II inhibitors. Their pattern of cytotoxic and cyostatic activity could be related to inhibition of protein tyrosine kinases. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.10.016

文献信息

• The Synthesis of Vinylogous Amidine Heterocycles
  作者：Daniel V. LaBarbera、Edward B. Skibo

  DOI：10.1021/jo401927n

  日期：2013.12.6

  We report herein a convenient synthetic methodology for the conversion of meta-dinitro heterocyclic rings to iminoquinones with vinylogous amidine functionality. These structures are found in nature, particularly in marine organisms, and may be important for the pigments and biological activity observed with such marine secondary metabolites. Using benzimidazole and indole ring systems we show the

  我们在这里报告了一种方便的综合方法，用于转换元-二硝基杂环成具有乙烯基am官能团的亚氨基醌。这些结构是在自然界中发现的，尤其是在海洋生物中，对于这些海洋次级代谢产物观察到的色素和生物活性可能很重要。使用苯并咪唑和吲哚环系统，我们展示了这些乙烯基ous的有机合成的通用性，包括以下内容：与几乎任何伯胺的氨基转移反应，对乙烯基am之间取代基的取代进行区域控制以及可控制的水解性能或根据所选环网系统的属性进行优化。在一起
• Non-basic melanin concentrating hormone receptor-1 antagonists
  申请人：Ahmad Saleem

  公开号：US20070093508A1

  公开（公告）日：2007-04-26

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式。此外，本申请提供了含有至少一种根据式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱（例如肥胖症、糖尿病、抑郁症或焦虑症）的患者的方法，通过给予根据式I的化合物的治疗有效剂量。
• 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS
  申请人：Engelhardt Harald

  公开号：US20090203673A1

  公开（公告）日：2009-08-13

  The present invention encompasses compounds of general Formula (I) wherein X and R 1 to R 3 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖一般式（I）中定义为权利要求1中定义的X和R1到R3的化合物，适用于治疗以细胞过度或异常增殖为特征的疾病，并且利用其制备具有上述特性的制药组合物。
• US7745447B2
  申请人：——

  公开号：US7745447B2

  公开（公告）日：2010-06-29
• US8258129B2
  申请人：——

  公开号：US8258129B2

  公开（公告）日：2012-09-04